1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF

BACKGROUND: Cabotegravir + rilpivirine (CAB+RPV) administered monthly or every 2 months (Q2M) is the only complete long-acting (LA) regimen for maintaining HIV-1 suppression and may address challenges associated with daily oral therapy. In the Phase 3b SOLAR study, switching to CAB+RPV LA Q2M was no...

Descripción completa

Detalles Bibliográficos
Autores principales: McKellar, Mehri, Teichner, Paula, Bettacchi, Christopher, Angel, Jonathan, Gordon, Lori A, Sutton, Kenneth, Sutherland-Phillips, Denise, Talarico, Christine L, Urbaityte, Rimgaile, Solingen-Ristea, Rodica Van, Baugh, Bryan, D’Amico, Ronald, van Wyk, Jean A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676875/
http://dx.doi.org/10.1093/ofid/ofad500.1422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676875/
http://dx.doi.org/10.1093/ofid/ofad500.1422

Ejemplares similares